Sign Out
Tenofovir Disoproxil Fumarate/Lamivudine/Efavirenz 300 mg/300 mg/400 mg Tablets is contraindicated in patients with clinically significant hypersensitivity to tenofovir, lamivudine, efavirenz or to any of the excipients contained in the formulation.
Herbal preparations containing St. John's wort (Hypericum perforatum) must not be used while taking Tenofovir Disoproxil Fumarate/Lamivudine/Efavirenz 300 mg/300 mg/400 mg Tablets due to the risk of decreased plasma concentrations and reduced clinical effects of efavirenz (see Interactions).
Efavirenz significantly decreases voriconazole plasma concentrations while voriconazole also significantly increases efavirenz plasma concentrations. Since Tenofovir Disoproxil Fumarate/Lamivudine/Efavirenz 300 mg/300 mg/400 mg Tablets is a fixed-dose combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Tenofovir Disoproxil Fumarate/Lamivudine/Efavirenz 300 mg/300 mg/400 mg Tablets must not be co-administered (see Interactions).
Co-administration with elbasvir (EBR) and grazoprevir (GZR) due to the potential for significant decreases in plasma concentrations of EBP and GZR.
Continue with Google